Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.
about
Role of the p53/p21 system in the response of human colon carcinoma cells to DoxorubicinCurtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatmentNanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein traffickingA Physical Mechanism and Global Quantification of Breast CancerEstablishment of okadaic acid resistant cell clones using a cDNA expression library.Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 statusReduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexP53: an ubiquitous target of anticancer drugs.Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).Amifostine alleviates radiation-induced lethal small bowel damage via promotion of 14-3-3σ-mediated nuclear p53 accumulationDocetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: potential implication for prostate cancer therapyHIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs.Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyNCI's provocative questions on cancer: some answers to ignite discussion.An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.Wt p53 impairs response to chemotherapy: make lemonade to spare normal cellsDNA damage as an early biomarker of effect in human health.A genomic Multiprocess survey of machineries that control and link cell shape, microtubule organization, and cell-cycle progressionBis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells.Recent discoveries in the cycling, growing and aging of the p53 fieldRecent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitorsSilencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis.Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.Induction of apoptosis in human oral cancer cell lines, OC2 and TSCCa, by chingwaysan.Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis.Hyperploidy induced by drugs that inhibit formation of microtubule promotes chromosome instability.The role of p53 deacetylation in p21Waf1 regulation by laminar flow.
P2860
Q24801155-568C403B-F173-4E7C-AD2C-9671AFD7843FQ26823867-7D5AD40F-FB6F-4EE7-A24F-C9C14ACC8D27Q27011482-C0CBCDCD-B863-4706-9BB4-08084C37BFFEQ28596313-71C121B8-5497-4796-9A0E-4E1976FB5CA2Q30996073-345BA0A8-D9E8-47A4-94F0-51385EE05A8DQ33533630-5B5FA1DA-74AC-46F9-A522-8456C780AE0CQ33688600-F60EC09C-A438-4008-A4A4-8577C3A3BCE9Q33718131-98D8AB52-B95D-4811-87FA-E5D95E40B624Q34539978-5133B722-11D9-4DC7-8D07-ECCD5A2BF79DQ34541922-C79BBDA4-3469-48C6-9A4C-3B40B2D3BAF2Q34654628-46F99285-22C8-4476-AC93-9810B9F87F5CQ35019472-5E39D508-9AB7-4CB8-BB40-B53E04255EF7Q35051166-D1711E1B-38C5-4E68-8626-70CA4B475CEAQ35679387-FD4188D9-1EFB-4BCF-95DA-082545AC0B70Q35740145-1A9C8B65-720F-4847-9463-68FACDEE98B4Q35764401-CAF2AFFF-DA5D-414C-AFA7-964A8D81F89EQ36023740-82AAC781-2457-4EC3-BB88-02522EDC758EQ36234051-00A20825-4143-4FFE-8D1D-E7FDBE03F438Q36252134-8EF96E45-814D-4B1E-9D5E-F2FC3D596909Q36288192-00482E2F-C8A3-4B92-96A3-05A82271FB35Q36562191-F69E537D-1F89-4B86-9817-5263FDF7A042Q36736358-72A86938-CD71-44BD-AF0D-F6AFC0AE9A82Q36926098-C9B188AF-5048-4713-B27D-FF0D500C1472Q36926148-B85442F4-3D1B-46DB-82B2-680BF664BCD5Q37385293-6EF6268B-D941-4FDD-9028-50F48BF47195Q37520284-6683AAB4-BE4F-48A5-A6C6-1FD1295692F9Q37625849-DE70ABFD-C482-431B-9530-8C32504B4D09Q38261022-702674C6-D388-4732-AA21-CFAA9B2AC85EQ38993174-E6DE4847-579D-4AF7-A182-F2D767880D91Q39398543-608FB698-F957-463E-A0FB-B27452014BD9Q39938202-1ECDE35A-D096-429C-BDA2-219790EC779BQ40300559-41BAC17C-047B-4AAA-BFF2-22FEAD328A8DQ40432340-3C4F16E3-31E5-4A0F-B49A-A4E70B730CF3Q40794489-AF978A23-DBDC-46D7-B0EA-C2D51FEB8A45Q40833596-E6749B04-C780-4B80-973D-A6A64CE94D9FQ41561051-38F2D884-D6C7-4789-A047-1EC5B357A13BQ43718785-000F6F88-53CA-477D-8555-2994A2747CCEQ43918452-CCF06927-521F-4543-A65D-638535DE0CE4Q44418946-401B9F15-C902-4452-B242-1F6ED13A9092
P2860
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@ast
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@en
type
label
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@ast
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@en
prefLabel
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@ast
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@en
P2093
P2860
P356
P1476
Pretreatment with DNA-damaging ...... s by microtubule-active drugs.
@en
P2093
P2860
P304
P356
10.1172/JCI8625
P407
P577
2000-02-01T00:00:00Z